RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology

RNA先驱和生物技术革新者加入TransCode Therapeutics科学顾问委员会，推动RNA肿瘤学发展。

Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drug

2002年，扎莫雷博士共同创立了Alnylam制药公司，该公司开发并商业化了首个获FDA批准的RNAi药物。

BOSTON

波士顿

,

，

May 28, 2025

2025年5月28日

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq:

/PRNewswire/ -- TransCode Therapeutics, Inc.（纳斯达克：

RNAZ

RNAZ

), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of

），一家临床阶段的肿瘤学公司，正在开发用于治疗癌症的RNA靶向疗法，今天宣布任命

Phillip D. Zamore

菲利普·D·扎莫雷

, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr

，博士，加入其科学顾问委员会。扎莫雷博士是一位著名的生物技术革新者，以其在RNA干扰（RNAi）领域的开创性工作而闻名。他与包括诺贝尔奖得主在内的世界知名科学家们一起工作。

Phillip Sharp

菲利普·夏普

, he co-founded Alnylam Pharmaceuticals in 2002, which developed the first FDA-approved RNAi drug.

，他于2002年共同创立了Alnylam Pharmaceuticals，该公司开发了首个获FDA批准的RNAi药物。

Dr. Zamore currently serves as the Gretchen Stone Cook Professor of Biomedical Sciences at the

扎莫雷博士目前担任格雷琴·斯通·库克生物医学科学教授

University of Massachusetts

马萨诸塞大学

Chan Medical School, where he chairs the RNA Therapeutics Institute. Dr. Zamore's research has significantly advanced the understanding of non-coding RNA and its role in health and disease. He helped uncover how microRNAs are processed and incorporated into RNA-induced gene-silencing complexes. His contributions have been recognized by his election to the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences..

陈医学院，他担任RNA治疗研究所所长。Zamore博士的研究极大地推动了对非编码RNA及其在健康和疾病中作用的理解。他帮助揭示了微小RNA如何被加工并整合到RNA诱导的基因沉默复合体中。他的贡献得到了认可，当选为美国国家科学院、美国国家医学院和美国艺术与科学院院士。

'We are honored to welcome Dr. Zamore to our Science Advisory Board,' said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. 'His deep expertise in RNA biology and his track record of translating scientific discoveries into therapeutic innovations will be invaluable as we advance our pipeline of RNA-targeted cancer therapies.'.

“我们很荣幸欢迎扎莫雷博士加入我们的科学顾问委员会，”TransCode Therapeutics公司的首席科学官兼联合创始人兹德拉夫卡·梅达罗娃博士说，“他在RNA生物学方面的深厚专业知识以及将科学发现转化为治疗创新的成就，将为我们推进RNA靶向癌症治疗管线提供巨大价值。”

'TransCode's approach to targeting metastatic cancer through RNA therapeutics is both innovative and promising,' said Dr. Zamore. 'I look forward to contributing to the company's mission of developing effective RNA-based treatments for patients with cancer.'

“TransCode公司通过RNA疗法靶向治疗转移性癌症的方法既创新又前景广阔，”扎莫雷博士说道。“我期待为公司开发基于RNA的有效癌症治疗方法的使命做出贡献。”

About TransCode Therapeutics

关于TransCode治疗学

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.

TransCode是一家临床阶段的肿瘤学公司，专注于治疗转移性疾病。该公司致力于通过其专有的TTX纳米粒子平台智能设计和有效递送RNA疗法来战胜癌症。该公司的主要治疗候选药物TTX-MC138专注于治疗过表达microRNA-10b的转移性肿瘤，microRNA-10b是转移的一种独特且有充分文献记录的生物标志物。

In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. .

此外，TransCode 还拥有其他一系列首创的 RNA 治疗候选药物，旨在克服 RNA 递送的挑战，从而解锁对多种新型遗传靶点的治疗通道，这些靶点可能与治疗多种癌症相关。

Forward-Looking Statements

前瞻性声明

This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements about microRNAs and their involvement in cancer, statements concerning the therapeutic potential of TransCode's TTX-MC138 and other therapeutic candidates, and statements concerning TransCode's TTX nanoparticle platform.

本发布包含1995年《私人证券诉讼改革法案》所指的“前瞻性声明”，包括但不限于关于microRNA及其在癌症中的作用的声明，关于TransCode的TTX-MC138及其他治疗候选药物的治疗潜力的声明，以及关于TransCode的TTX纳米粒子平台的声明。

Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

本新闻稿中的任何前瞻性陈述均基于管理层对未来事件的当前预期，并受多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些前瞻性陈述中或暗示的结果存在重大差异且产生不利影响。

These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 corona.

这些风险和不确定性包括但不限于：与药物发现和开发相关的风险；临床试验结果与TransCode的临床前研究、预期或以往临床试验结果不一致的风险；与临床试验实施相关的风险；与TransCode财务状况及其需要获取额外资金以支持其业务活动相关的风险，包括TransCode能否持续经营的风险；与TransCode计划中的监管提交的时间和结果相关的风险；与获取、维护和保护知识产权相关的风险；与TransCode执行其专利对抗侵权者及防御第三方对其专利组合发起挑战的能力相关的风险；来自其他开发类似用途产品的公司竞争的风险；与TransCode对第三方依赖相关的风险；以及与地缘政治事件和疫情（包括COVID-19冠状病毒）相关的风险。

December 31, 2024

2024年12月31日

, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law. .

以及在TransCode随后向证券交易委员会提交的文件中讨论的潜在风险、不确定性和其他重要因素。本新闻稿中的所有信息均为本发布日期当日的信息；除非法律要求，TransCode不承担更新此信息的责任。

SOURCE TransCode Therapeutics, Inc.

源代码：TransCode Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用